Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crystalvue Medical CoROCO:6527 -0.28%94 EBITDA Margin % is 21.53% as of Dec. 2025, which is 12% above its 10-year median of 19.17. GuruFocus rates ROCO:6527 with a GF Score™ of 94/100 and a GF Value™ of NT$95.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Crystalvue Medical Co ranks better than 77.08% on this metric.
Crystalvue Medical Co (ROCO:6527) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Crystalvue Medical Co EBITDA Margin % Related Terms
Crystalvue Medical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Crystalvue Medical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6527 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Crystalvue Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crystalvue Medical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Crystalvue Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Crystalvue Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crystalvue Medical Co (ROCO:6527) has a EBITDA Margin % of 21.53% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Crystalvue Medical Co and its competitors. This is 12% above median its historical median of 19.17. Over the past decade, Crystalvue Medical Co's EBITDA Margin % has ranged from 9.50 to 21.81. According to the industry distribution chart, Crystalvue Medical Co ranks #187 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.9%.
Is Crystalvue Medical Co's EBITDA Margin % too high?
Crystalvue Medical Co's current EBITDA Margin % of 21.53% is 12% above median its 10-year median of 19.17. Over the past 10 years, this metric has ranged from a low of 9.50 to a high of 21.81. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Crystalvue Medical Co's value of 21.53% is 188.8% above this industry median. Based on the distribution chart, Crystalvue Medical Co ranks #187 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Crystalvue Medical Co has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Crystalvue Medical Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Crystalvue Medical Co ranks #187 out of 816 companies for EBITDA Margin %. This places Crystalvue Medical Co in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.46. Crystalvue Medical Co's value of 21.53% is 188.8% above this benchmark. Historically, Crystalvue Medical Co's own EBITDA Margin % has ranged from 9.50 to 21.81 over the past decade. While the company's 10-year median is 19.17 vs. the industry median of 7.46, Crystalvue Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crystalvue Medical Co's current EBITDA Margin % of 21.53% is 188.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Crystalvue Medical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crystalvue Medical Co's current EBITDA Margin % is 21.53%, which is 12% above median its own 10-year median of 19.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crystalvue Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Crystalvue Medical Co (ROCO:6527) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$95.37, compared to a current price of NT$71.00 — trading 25.6% below its estimated fair value. The current EBITDA Margin % is 21.53%, which is 12% above median its 10-year median of 19.17 and 188.8% above the Medical Devices & Instruments industry median of 7.46. Crystalvue Medical Co's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Crystalvue Medical Co (ROCO:6527), the current EBITDA Margin % is 21.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crystalvue Medical Co (ROCO:6527) Overvalued in 2026?
Based on GuruFocus' analysis, Crystalvue Medical Co stock appears to be undervalued.
The current stock price of NT$71.00 is trading 25.6% below its estimated GF Value™ of NT$95.37.
GuruFocus considers Crystalvue Medical Co to be Modestly Undervalued.
Key valuation signals for ROCO:6527:
EBITDA Margin %: 21.53% (12% above median its 10-year median of 19.17)
GF Value™: NT$95.37 vs. price of NT$71.00 (25.6% below fair value)
Industry Position: 188.8% above the Medical Devices & Instruments median (#187 of 816)
No single metric tells the full story. See the ROCO:6527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crystalvue Medical Co Ltd is engaged in the manufacture and sale of medical devices. Its products include fundus cameras, optical coherence tomography (OCT) systems, tonometers, digital microscope cameras, lens edgers, and gastrointestinal endoscopic disposable devices, among others.
94GF Score
Get the complete analysis for ROCO:6527
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6527 has been successfully added to your 
